Connor, Clark & Lunn Investment Management (CC&L)
KPTI icon

Connor, Clark & Lunn Investment Management (CC&L)’s Karyopharm Therapeutics KPTI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$746K Sell
76,397
-2,684
-3% -$23.3K ﹤0.01% 1279
2026
Q1 		$440K Buy
79,081
+21,869
+38% +$167K ﹤0.01% 1335
2025
Q4 		$421K Buy
+57,212
New +$350K ﹤0.01% 1331
2024
Q2 		– Sell
-5,088
Closed -$115K – 1535
2024
Q1 		$115K Buy
5,088
+340
+7% +$5.96K ﹤0.01% 1455
2023
Q4 		$61.6K Buy
4,748
+2,396
+102% +$32.3K ﹤0.01% 1334
2023
Q3 		$47.3K Sell
2,352
-147
-6% -$3.3K ﹤0.01% 1321
2023
Q2 		$67.1K Sell
2,499
-9,998
-80% -$431K ﹤0.01% 1262
2023
Q1 		$729K Sell
12,497
-16,322
-57% -$806K ﹤0.01% 798
2022
Q4 		$1.47M Buy
28,819
+18,457
+178% +$1.28M 0.01% 618
2022
Q3 		$849K Buy
10,362
+7,297
+238% +$545K 0.01% 693
2022
Q2 		$207K Buy
+3,065
New +$281K ﹤0.01% 932
2019
Q3 		– Sell
-3,845
Closed -$346K – 1023
2019
Q2 		$346K Sell
3,845
-4,885
-56% -$392K ﹤0.01% 796
2019
Q1 		$765K Buy
+8,730
New +$968K 0.01% 585
2016
Q2 		– Sell
-1,820
Closed -$244K – 901
2016
Q1 		$244K Sell
1,820
-920
-34% -$102K ﹤0.01% 687
2015
Q4 		$545K Buy
2,740
+68
+3% +$14.7K ﹤0.01% 526
2015
Q3 		$422K Sell
2,672
-375
-12% -$100K ﹤0.01% 550
2015
Q2 		$1.24M Buy
3,047
+107
+4% +$46.2K 0.01% 303
2015
Q1 		$1.35M Buy
2,940
+2,207
+301% +$951K 0.01% 274
2014
Q4 		$412K Buy
+733
New +$416K ﹤0.01% 420

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KPTI Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Karyopharm Therapeutics (KPTI) stake by 3.4% in Q2 2026, selling an estimated $23.3K and leaving 76,397 shares worth $746K. The position accounts for ﹤0.01% of the portfolio, ranked #1279.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KPTI in Q4 2014 and has held it in 19 quarters since. The position peaked at $1.47M in Q4 2022. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 76,397 shares of Karyopharm Therapeutics worth $746K as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 2,684 Karyopharm Therapeutics shares in Q2 2026, an estimated $23.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1279 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Karyopharm Therapeutics in Q4 2014 and has held it in 19 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Karyopharm Therapeutics position peaked at $1.47M in Q4 2022.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.